Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus TASCENSO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus TASCENSO ODT.
FINGOLIMOD HYDROCHLORIDE vs TASCENSO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, inducing internalization and degradation of the receptor, thereby preventing egress of lymphocytes from lymph nodes, reducing peripheral lymphocyte count and immune-mediated demyelination in the central nervous system.
0.5 mg orally once daily
14 mg orally once daily, with or without food. Swallow whole; do not crush, chew, or dissolve.
None Documented
None Documented
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Terminal elimination half-life is 48-56 hours, supporting once-daily dosing.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Renal: ~80% unchanged; biliary/fecal: ~20% as metabolites.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator